Intravenous beta-endorphin administration fails to alter hypothalamic blood flow in rats expressing normal or reduced nitric oxide synthase activity

Peptides. 1996;17(4):733-6. doi: 10.1016/0196-9781(96)00065-4.

Abstract

beta-Endorphin (beta-END) significantly contributes to the maintenance of hypothalamic blood flow (HBF) autoregulation during hemorrhagic hypotension in rats. Recently, several natural and synthetic opioid peptides were reported to induce nitric oxide (NO)-mediated dilation in the cerebrovascular bed. In the present study, the effect of beta-END was studied on HBF and hypothalamic vascular resistance (HVR) in vehicle-treated control rats and in rats after the pharmacological inhibition of the NO synthesis by chronic oral application of NG-nitro-L-arginine methyl ester. Intravenous beta-END administration failed to alter HBF or HVR either in control or in NO-blocked animals, and its transient hypotensive effect was not inhibited by NO blockade, indicating that beta-END may not have NO-mediated vasodilator effect in the hypothalamic or in the systemic circulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Pressure / drug effects*
  • Carbon Dioxide / blood
  • Heart Rate / drug effects*
  • Hemoglobins / metabolism
  • Hydrogen-Ion Concentration
  • Hypothalamus / blood supply*
  • Injections, Intravenous
  • Male
  • NG-Nitroarginine Methyl Ester / pharmacology*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase / metabolism*
  • Oxygen / blood
  • Partial Pressure
  • Rats
  • Rats, Sprague-Dawley
  • Regional Blood Flow / drug effects
  • Vascular Resistance / drug effects*
  • beta-Endorphin / administration & dosage
  • beta-Endorphin / pharmacology*

Substances

  • Hemoglobins
  • Carbon Dioxide
  • beta-Endorphin
  • Nitric Oxide Synthase
  • Oxygen
  • NG-Nitroarginine Methyl Ester